Himalaya Nutravedics IPO Analysis: Should You Apply? GMP, Review & Details

Himalaya Nutravedics is a SME IPO in the Other Food Products sector. The issue price band is ₹100.0–₹106.0 per share. Issue size is ₹26.5 crore.

Himalaya Nutravedics IPO — Key Details

Company Overview

Himalaya Nutravedics India Ltd is engaged in the manufacturing, marketing, and distribution of Ayurvedic and nutraceutical formulations in India. The company operates a hybrid business model, balancing its own branded products with third-party contract manufacturing. Its product range includes classical Ayurvedic formulations, proprietary products, and nutraceutical supplements, available in various dosage forms. The company has an integrated manufacturing facility in Hyderabad and distributes its products across several Indian states, focusing on wellness and therapeutic segments.

Financial Performance

Revenue was ₹14.43 Cr in the year ending 31 Mar 2024, rising to ₹21.00 Cr by 31 Mar 2025, and further increasing to ₹43.12 Cr by 31 Mar 2026. This shows a strong upward trend in total income over the periods. Profit After Tax was ₹0.43 Cr in the year ending 31 Mar 2024, increasing to ₹2.23 Cr by 31 Mar 2025, and further rising to ₹7.39 Cr by 31 Mar 2026. This indicates substantial growth in profitability over the reported periods.

Objects of the Issue

The Company proposes to utilize the Net Proceeds from the Issue towards the following objects: 1. Funding Working Capital Requirements - ₹13.75 Cr 2. Business Development and Digital Marketing Activities - ₹7.50 Cr 3. General Corporate Purposes - Total ₹21.25 Cr.

Strengths & Weaknesses

Strengths

Integrated multi-dosage manufacturing capability, doctor acceptance supported by product performance rather than mass advertising, long-standing relationships with suppliers and customers, geographic expansion achieved over a relatively short operating history, and broad therapeutic coverage across the Ayurvedic and nutraceutical segment.

Understanding Grey Market Premium (GMP)

The Grey Market Premium (GMP) is an unofficial indicator of the expected listing price of an IPO. It reflects the demand and supply dynamics in the grey market and can provide insights into investor sentiment before the official listing. However, GMP is not a guaranteed predictor of actual listing gains.

Subscription Status

The IPO has received a total subscription of 2.33 times as of 24th Sep 2026. The breakdown includes 1.0 times from Qualified Institutional Buyers (QIB), 3.58 times from Non-Institutional Investors (NII), and 2.56 times from Retail Individual Investors (RII).

Peer Comparison

• Himalaya Nutravedics has a P/E ratio of 9.04, which is lower than its peers Sandu Pharmaceuticals Ltd. at 20.62 and Jeena Sikho Lifecare Ltd. at 26.75.

IPO Timeline

The IPO opens for subscription on 22nd September 2026 and closes on 24th September 2026. Allotment of shares will be done on 25th September 2026, with the listing expected on 29th September 2026.

Should You Apply for Himalaya Nutravedics IPO?

Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their overall investment strategy and risk tolerance. It is advisable to consider the company's growth potential and market position.

Investors with a low-risk appetite or those seeking guaranteed short-term returns may want to avoid IPOs like this, as they can be subject to market fluctuations and uncertainties.

This is general risk-profile education, not a personal recommendation to apply or avoid this specific IPO — TopFund is not a SEBI-registered investment adviser.

Listing Day Risks

Listing-day gains can be unpredictable and depend on various factors such as market conditions, investor sentiment, and overall demand for the stock. Investors should be cautious and not rely solely on potential listing gains when making investment decisions.

Trending Searches

Disclaimer: This is educational content, not investment advice. GMP is an unofficial grey-market indicator, unregulated and never guaranteed. TopFund is not a SEBI-registered investment adviser — please do your own research or consult a qualified adviser before applying to any IPO.